

# Computational Modelling of Atherosclerosis

Andrew Parton<sup>1</sup>, Victoria McGilligan<sup>1</sup>, Maurice O’Kane<sup>2</sup>, Francina R  
Baldrick<sup>1</sup>, Steven Watterson<sup>1\*</sup>

<sup>1</sup>Northern Ireland Centre for Stratified Medicine, Ulster University, C-TRIC, Altnagelvin Hospital  
Campus, Derry, Co Londonderry, Northern Ireland, BT47 6SB

<sup>2</sup>Department of Clinical Chemistry, Altnagelvin Hospital, Western Health and Social Care Trust,  
Londonderry, Northern Ireland, BT47 6SB

\*Corresponding author

## Author description

Andrew Parton is a doctoral student at the Northern Ireland Centre for Stratified Medicine, Ulster University. His interests are in using computational approaches to stratify patients with cardiovascular disease.

Victoria McGilligan is an Assistant Professor at the Northern Ireland Centre for Stratified Medicine, Ulster University. Her interests are in inflammatory biomarkers for disease risk in personalized medicine.

Maurice O’Kane is a consultant chemical pathologist in the Western Health and Social Care Trust at Altnagelvin Hospital. His interests are in dyslipidaemia and clinical decision-making.

Francina R Baldrick is an Assistant Professor at the Northern Ireland Centre for Stratified Medicine, Ulster University. Her interests are in biomarkers for the role of nutrition in disease.

Steven Watterson is an Assistant Professor at the Northern Ireland Centre for Stratified Medicine, Ulster University. His interests are in computational modelling of cholesterol metabolism and cardiovascular disease.

### Key Points

- Atherosclerosis is a disorder that emerges from a combination of dynamic processes, making it well suited to computational modelling.
- Atherosclerosis has been modelled to a range of levels of detail in recent work.
- There have been relatively few studies of plaque rupture and thrombosis with most work focussing on atheroma formation.
- Many elements of atherosclerosis have not yet been modelled which we describe.
- This is the first review to bring together the latest work in the area.

# Computational Modelling of Atherosclerosis

Andrew Parton<sup>1</sup>, Victoria McGilligan<sup>1</sup>, Maurice O’Kane<sup>2</sup>, Francina R  
Baldrick<sup>1</sup>, Steven Watterson<sup>1\*</sup>

<sup>1</sup>Northern Ireland Centre for Stratified Medicine, Ulster University, C-TRIC, Altnagelvin Hospital  
Campus, Derry, Co Londonderry, Northern Ireland, BT47 6SB

<sup>2</sup>Department of Clinical Chemistry, Altnagelvin Hospital, Western Health and Social Care Trust,  
Londonderry, Northern Ireland, BT47 6SB

\*Corresponding author

Atherosclerosis is one of the principle pathologies of cardiovascular disease with blood cholesterol a significant risk factor. The World Health Organisation estimates that approximately 2.5 million deaths occur annually due to the risk from elevated cholesterol with 39% of adults worldwide at future risk. Atherosclerosis emerges from the combination of many dynamical factors, including haemodynamics, endothelial damage, innate immunity and sterol biochemistry. Despite its significance to public health, the dynamics that drive atherosclerosis remain poorly understood. As a disease that depends on multiple factors operating on different length scales, the natural framework to apply to atherosclerosis is mathematical and computational modelling. A computational model provides an integrated description of the disease and serves as an *in silico* experimental system from which we can learn about the disease and develop therapeutic hypotheses. Although the work completed in this area to-date has been limited, there are clear signs that interest is growing and that a nascent field is establishing itself. This paper discusses the current state of modelling in this area, bringing together many recent results for the first time. We review the work that has been done, discuss its scope and highlight the gaps in our understanding that could yield future opportunities.

## Introduction

Cardiovascular disease (CVD) is the primary cause of death globally [1] and contributes to morbidity and mortality more than any other disorder in the western world [2]. In 2012, CVD was responsible for 31% of deaths worldwide, 47% of all deaths within Europe and 40% of all deaths within the European Union [3, 4]. CVD covers a collection of disorders that can be split into atherosclerotic and non-atherosclerotic categories [1]. Atherosclerotic CVD includes cerebrovascular disease [5], coronary artery disease [6] and peripheral vascular disease [7], and it is responsible for the majority of instances of CVD with a 2012 estimate attributing 71% of all CVD to atherosclerotic forms [4].

At least 75% of all CVD-related deaths occur in low and middle-income countries [3]. In China, more than 4% of the gross national income is directly spent on the treatment of CVD [8] and in the EU, it is estimated that CVD costs the economy approximately €196 billion per year [4]. Improvements in atherosclerosis and CVD treatment therefore have the potential to make a dramatic impact, not only on the quality of care available, but also on the economics of healthcare.

CVD is predominantly an age related condition. Coronary heart disease in men occurs five times more frequently in 80+ year old patients than similar patients in the 40-59 age group [9]. It is predicted that the global population aged 60+ will rise from 11% in the year 2000 [10] to 22% in 2050, making atherosclerosis a significant future public health concern. Comorbidities that drive CVD, such as diabetes [11], are set to grow with a global increase of 55% in cases projected between 2013 and 2035 [12]. The current and growing global risk of morbidity and mortality from atherosclerosis and the economic burden of treatment therefore make atherosclerosis an important area of future research.

Despite the growing importance of atherosclerosis and its implications for public health, its pathogenesis is not fully understood [13]. Traditionally, atherosclerosis was viewed as a build-up of lipids (including cholesterol) within the innermost layer of the artery wall (the *tunica intima*) [14].

However, our understanding has since developed and atherosclerotic CVD is now predominantly viewed as a chronic inflammatory condition, advanced by lipid build-up and triggered by innate immune responses [13, 15].

Atherosclerosis emerges as the results of multiple dynamical cell processes. Damage to endothelial cells [16] recruits monocytes to the site of inflammation via inter- and intra-cellular signalling [17]. Monocytes migrate into the artery wall [18], alongside lipoproteins, before differentiating into macrophages and phagocytosing oxidised low density lipoproteins (oxLDL) [19, 20]. The migration rate of these cells and particles is dependent upon haemodynamics [21] and vascular mechanical stress [22]. The accumulation of cholesterol-laden macrophages within the artery wall leads to plaque formation [23].

Studies aimed at understanding atherosclerosis need to be broad in scope and integrative in nature. The appropriate framework in which to consider emergent dynamical behaviour of this type is mathematical and computational modelling. A comprehensive programme of mathematical modelling and simulation can provide many benefits. Principally, it yields a framework for therapeutic hypothesis generation and for *in silico* drug target identification with the potential to streamline the drug development pipeline. This framework can be applied across populations or can be tuned to describe individual patients or patient groups as part of a programme of stratified, personalised and precision medicine [24].

Mathematical and computational models can take a range of forms. Ordinary differential equations (ODEs) [25], partial differential equations (PDEs) [25] and stochastic ordinary differential equations (SODEs) [26], alongside binary [27] and multivalued [28] logic have all been used to model pathway dynamics. Process algebras such as pi [29] and kappa [30] calculus have been used to capture the structure of pathway systems, in particular addressing the exponential growth in possible network configurations to be considered as the number of pathway components increases [31, 32].

Statistical models that infer pathway structure have been used to generate hypotheses from existing datasets [33, 34].

Computational biology approaches have previously been applied in studies of a range of dynamical disease processes. Examples include studies of Alzheimer's disease in which the pathways that mediate brain energy metabolism have been elucidated [35], studies of diabetes in which models of diagnostic testing have been developed along with models of the physiological mechanisms associated with disease [36] and studies of breast cancer in which biomarkers have been identified for the stratification of patient treatment [37]. Furthermore, computational models have been applied to pathway systems such as nuclear factor kappa beta (NF- $\kappa$ B) signalling [38], macrophage processing [39], human metabolism [40] and iron metabolism [41]. In one of the more ambitious computational studies of recent years, the first computational model of whole cell activity has appeared describing *Mycoplasma genitalium* [42].

Machine-readable standards for model representation have been developed to assist model development and model reuse. These standards have stimulated the creation of pathway informatics tools and have made models independent of the software tools used to create them. In particular, the Systems Biology Markup Language (SBML) [43, 44] and CellML [45] file formats capture ODE models describing the kinetics of pathway interactions and the Systems Biology Graphical Notation Markup Language (SBGN-ML) [46, 47] encodes diagrams of pathway function in a biologically meaningful file format. The Minimum Information Requested in the Annotation of Biochemical Models (MIRIAM) [48] and Minimum Information About a Simulation Experiment (MIASE) [49] standards describe model annotation and use respectively, and online repositories of SBML files have been introduced to facilitate model reuse [50].

Previously, cholesterol biosynthesis and the impact of therapeutic interventions have been modelled in a series of computational studies [51–55] and the role of lipid metabolism and CVD in aging has been reviewed [56]. However, no review has yet brought together the significant volume of recent

work completed on computational modelling of atherosclerosis. This paper reviews the current state of this important nascent field, describing the work completed to date, discussing the approaches taken and highlighting the gaps in our understanding.

## The pathophysiology of atherosclerosis

In Figure 1, we see a representation of the processes that lead to atherosclerosis [13, 57, 58]. Damage to the endothelial layer of the artery wall triggers an inflammatory response in which monocytes, T-lymphocytes and other immune cells are recruited to the region of damage. These cells penetrate the endothelial layer, reaching the *tunica intima*, along with low density lipoprotein (LDL) and high-density lipoprotein (HDL) particles. Stimulated by the presence of interferon gamma (IFN- $\gamma$ ) and macrophage colony stimulating factor (M-CSF), monocytes differentiate into macrophages once they have entered the artery wall. While embedded within the *tunica intima*, both LDL and HDL become oxidized by free oxygen radicals. Macrophages will phagocytose oxidized LDL (oxLDL), but not oxidized HDL. Macrophages heavily loaded with oxLDL transform into foam cells that eventually undergo apoptosis. The resulting mass of debris embedded in the *tunica intima* is known as an atheroma. Foam cells, along with endothelial cells, secrete monocyte chemoattractant protein-1 (MCP-1) to recruit more monocytes to the site of inflammation. Naïve T cells contained within the artery wall differentiate into individual T cell types that can secrete IFN- $\gamma$ . Smooth muscle cells (SMCs) are also recruited into the *tunica intima* where they undergo apoptosis and contribute to the formation of a fibrous cap in the artery wall. This accumulation of cells and debris can cause a swelling of the artery wall that restricts blood flow, leading to stenosis. If the fibrous cap ruptures, the build-up in the *tunica intima* is released into the blood stream increasing the risk of blockages downstream. Further complications can occur including clotting at the site of the atheroma where a thrombus forms further impeding blood flow.

## Computational modelling

### *Blood flow dynamics*

Vascular damage is a key trigger for the onset of atherosclerosis that can be induced by factors such as hypertension [59], smoking [60] and oxidative stress [61]. The elastic properties of arteries under hypertensive pressure have been modelled previously [62]. Obstructions to blood flow are known to



be atherogenic [63] and it has been shown that this is in part attributable to the turbulent blood flow likely to be induced downstream [21, 22, 64–66].

A number of computational studies have modelled the dynamics of blood flow (*haemodynamics*) and its relationship to vascular structure. Navier-Stokes equations are typically used to describe blood flow through arterial structures [62–64, 66–82] under the assumption that blood flows as a Newtonian fluid, an approximation that can be violated by its viscosity and granularity. However, Navier-Stokes systems are well studied and are therefore represent a powerful framework for computational analysis. Arterial wall shear stress (WSS) is widely used as a model output that serves as a marker for atherosclerotic prone regions within an artery [21, 66, 67, 69–73, 76, 78–86]. How WSS impairs endothelial function is not well known, although its physiological significance has been demonstrated [22]. Two-dimensional and three-dimensional models of a Y-shaped arterial branch [66, 70, 71, 80, 83, 85–87] have been created along with linear artery models [64, 67, 68, 70–75, 78, 81, 88, 89]. Lower dimensional models are less physiologically accurate, but they provide the authors with more computationally amenable frameworks in which to demonstrate important principles, such as plaque stability [64] and the impact of stenosis [67].

Inflammation is thought to be driven by the penetration of the arterial wall by LDL, which in some cases is taken to be a function of the wall shear stress, demonstrating that an arterial branch can be a focal point for atheroma formation [66, 70, 71, 80, 81, 83, 85, 86]. As well as WSS, it has been shown that inflammation is related to blood viscosity, inlet flow rate and the geometry of the artery [73].

Simpler abstract models of this process have been developed that are less physiologically descriptive, but that enable more powerful mathematical approaches to be employed. They have been used to describe atherosclerosis as a bistable system for simple arterial geometries [84], to develop haemodynamic models in order to explore the turbulence downstream of an atherosclerotic

constriction in two dimensions [88] and to describe haemodynamics and plaque formation as a test case for novel numerical methods [90].

### *LDL concentration in the artery lumen*

The turnover of LDL in the blood plays an important role as a primary factor that affects LDL penetration of the *tunica intima* in many models of atherosclerosis. Plasma LDL levels have been modelled as constant [71, 77, 80, 87], or as a variable [68, 70, 71, 74, 78, 81, 85, 90, 91] where the system dynamics are typically governed by a series of convection-diffusion equations, or part of a combined mass flow [82].

### *LDL penetration of the tunica intima*

The process through which LDL passes into the *tunica intima* has been modelled at a range of levels. The simplest approaches consider this to be a mathematical function of arterial WSS [92] or constant [77, 87, 90, 91, 93, 94]. Some simply ignore LDL penetration, instead considering only LDL in the *tunica intima* [84] or combining cells, proteins and other macromolecules into one mixed quantity [95]. More sophisticated approaches have considered diffusion [68, 74, 78, 82, 85, 96, 97] and have modelled the artery wall as a semi-permeable membrane by utilising Kedem-Katchalsky equations [67, 71, 81, 98, 99]. LDL penetration appears to be considered as a boundary to many models and the description of its uptake reflects the scope of the model proposed.

### *LDL oxidation and the role of HDL*

A range of approaches have been taken to describe LDL oxidation inside the *tunica intima* and they are coupled to LDL penetration to differing extents. Many studies consider the synthesis and turnover of oxLDL directly [68, 71, 80, 81, 84, 86, 87, 90, 91, 93, 94, 96–98, 100, 101]. In some, oxidation of LDL is a modelled reaction [68, 71, 80, 81, 86, 87, 90, 91, 93, 94, 96, 97] whereas in others it is taken to be a process that is driven by factors such as monocyte recruitment [84] or is modelled as a constant [100, 101]. Intermediate stages of the oxidation process have been

considered by modelling the number of unoxidized antioxidant molecules attached to each LDL particle [94].

The role of HDL has been incorporated into a portion of these studies. In particular, it has been modelled as competing for free radicals and suppressing inflammatory signalling in the *tunica intima* [91, 94, 97] and as having an atheroprotective effect on foam cells [96, 101].

Elsewhere, the interplay between LDL, HDL, oxidising free radicals and antioxidant vitamins C and E have been studied [94] with predictions of comparable atheroprotective power between HDL and vitamin C.

### *Monocyte recruitment and chemoattractants*

Monocyte recruitment has been modelled as related to shear stress and the rate of LDL penetration [84]. The existence of monocytes in the lumen has rarely been considered [68], but several studies have modelled the turnover of monocytes in the *tunica intima* [68, 84, 91, 102, 103]. Elsewhere, the process of monocyte recruitment and differentiation has also been simplified and incorporated into one step governing macrophage turnover, where this is linked to driving factors such as shear stress, diffusion and LDL penetration [67, 80, 81, 86, 90, 93, 96–101].

Similarly, the turnover of MCP-1 as a chemoattractant has been described explicitly in some studies [96, 97] and grouped together with other chemoattractants including interleukin-1 (IL-1) and M-CSF in other studies [68, 86, 90, 91, 93, 99, 104]. One study has shown that exposure to radiation leads to enhanced levels of MCP-1 and is therefore atherogenic [103]. However, in many studies the role of chemoattractants has been ignored.

### *Monocyte to macrophage differentiation*

The differentiation of monocytes to macrophages has been incorporated into a number of studies, although many simplify this step by considering both populations as one group on the grounds that

differentiation occurs on a time scale too short to be significant [67, 71, 100]. Where differentiation has been modelled it is presented with mass action kinetics [68, 84, 91, 103].

### *Foam cell formation and the phagocytosis of oxidised LDL*

The transformation of macrophages to foam cells due to the phagocytosis of oxLDL is a critical stage in the formation of atheroma that has been included in many studies. These are typically modelled as a combination of mass action and Michaelis-Menten terms [67, 68, 80, 81, 84, 86, 96, 97, 100, 101], and in some cases reverse cholesterol efflux is included in the model [96, 101, 105]. Many studies, however, omit foam cell formation as a step, instead taking the volume of macrophages recruited to be representative of atheroma formation [91, 93, 98, 102, 104].

### *T cell recruitment and the role of interferon-gamma (IFN- $\gamma$ )*

The role of T cells in coordinating the inflammatory response has rarely been included in computational studies. Where they have been included as a factor, T cells yield IFN- $\gamma$  that modulates macrophage differentiation [91, 96, 97, 103] and are themselves modelled as being activated by interleukin 12 (IL-12) [96, 97], although it has been shown experimentally that T cells can also be activated by IL-1 [106] and IFN- $\gamma$  [107].

### *Proliferation of smooth muscle cells*

Along with foam cells and cell debris, SMCs contribute to the formation of atheroma [13]. However this factor has rarely been incorporated into models. Where it has been incorporated, SMC recruitment occurs in response to MCP-1, platelet derived growth factor (PDGF) and extracellular matrix (ECM) either modelled explicitly as factors [96, 97] or as a generic recruitment process [68, 90, 91, 93]. One study in particular has focused on the interplay between SMCs and PDGF identifying bistability in SMC-driven atheroma formation [108].

## *Plaque rupture and thrombosis*

The rupture of atheroma has been modelled, establishing a criterion for atheroma instability that takes the form of a solution to a third order non-linear ODE [88]. Separate studies have established stability by evaluating the eigenvalues of a perturbed system [93] and by calculating the mean *time-to-rupture* of atheroma formation [102]. The WSS upon an atheroma has been calculated as a trigger for rupture and this model has been modified to incorporate the effects of abnormal axial G-forces [89]. Relevant models have been produced that describe thrombus formation in the absence [109] and presence of shear blood flow [64, 110].

## **Discussion**

The models described here are summarised in Table 1. The majority of the work presented has been published in the last 10 years, demonstrating that computational modelling of atherosclerosis is a developing field with growing support. These studies operate at a range of levels of abstraction and have variable scope. However, they have all been produced as separate bespoke computational models with little capacity for reuse by the wider modelling community. The adoption of community modelling standards such as SBML [43, 44] and SBGN-ML [46, 47] would enable the community to progress together on the development of atherosclerosis modelling and it would be a valuable exercise to translate the most biologically detailed models [68, 81] into these community standards.

Online databases, such as BioModels [50, 111, 112] and the Physiome Model Repository 2 (PMR2) [113], contain computational models of biological processes. Such databases facilitate the codification of our understanding and, critically, enable models to be reused and built upon as our knowledge advances. However, no models of atherosclerosis currently exist within these repositories, although systems biology representations of the cardiovascular system [114] and statin pharmacokinetics [115] are available.

The integration of models developed by different authors is likely to be a significant future challenge. The introduction of an online platform that presents networks of pathway diagrams using SBGN standards and enables users to select individual pathways or groups of pathways to study in isolation or to be downloaded for offline use, using SBGN-ML and SBML standards, would facilitate model reuse, maximising the value gained from their construction and enabling the research community to develop a coordinated consensus around the pathway biology more rapidly. Such a platform would not be limited to atherosclerosis but could be applied more broadly across pathway biology.

### *Factors not yet modelled*

There are many components of atherosclerosis that to date have not been modelled. With accurate parameterisation each would increase the comprehensiveness and accuracy of our understanding of atherosclerosis as a dynamical process. Triglyceride rich lipoproteins contribute to plaque build-up with some studies showing that they trigger foam cell formation through mechanisms that bypass LDL oxidation [116–118]. Elsewhere, it has been proposed that categories of HDL and their relative proportions may be more important than the absolute abundance of HDL [57, 119], suggesting that models could be adapted to incorporate a HDL profile that influences oxidation and reverse cholesterol efflux. It has also been shown that HDL can inhibit the recruitment of monocytes and subsequently reduce atherogenesis [120] suggesting further interactions to model. Clinically, it has been suggested that LDL particle number is a stronger risk factor for atherosclerosis than the abundance of LDL-bound cholesterol, implying that future models should include a description of the cholesterol load of lipoproteins as well as their abundance [121]. In addition, the role of neutrophils [122], nitrous oxide [57], B cells [123], heat shock proteins [124, 125], sterol regulatory element binding protein (SREBP) mediated regulation [54], various cell signalling proteins such as NLRP3 [126], and miRNAs [127] have not been modelled in this context.

By far the majority of work to date has been on the build-up of atheroma. Some studies have addressed the mechanisms through which atheroma rupture, but they are in a significant minority. Very little work has been done on the consequences of rupture, such as thrombus formation. This presents a potential direction for the field that is highly relevant to patient treatment as most patients at risk of CVD are only identified after a cardiovascular event has occurred.

### *Computational modelling in therapy development*

The application of computational modelling to therapy development in atherosclerosis has been historically poor. It is possible to predict both the efficacy of a drug and its potential side effects [128–130] and there is growing interest in areas of combinatorial drug design [131] to optimise treatment. Such approaches have been demonstrated for the role of statins in the reduction of LDL levels in plasma along with dietary changes [51, 97]. Computational biology can also be used to identify potential molecular targets for drugs and has been used to reduce the high attrition rate of drug discovery [133]. However, these technologies have yet to be exploited to their full potential. Finite element and analytical methods have been employed to model the interaction between a stent and artery wall when widening constricted arteries during angioplasty [134, 135].

Creating more comprehensive models of atherosclerosis has the potential to improve the efficiency of therapy development with benefits for both the patient and the commercial vendor. However, obtaining accurate parameterisations for the models is a fundamental challenge. The lack of appropriate published experimental data is a critical obstacle to generating high confidence predictive models.

### *Difficulties in model generation*

Developing a comprehensive predictive model of atherogenesis comes with many challenges. Our knowledge of the processes involved has increased significantly in recent years with the development of genomic technologies such as genome wide association studies (GWAS) [136]. As atherosclerosis is a cardiovascular condition that affects critical circulatory systems, studying human

atheroma poses logistical and ethical problems as access to live atherosclerotic tissue is limited and disturbances risk triggering plaque rupture. Consequently, data is limited. Animal studies of atherosclerosis do exist for mouse, rabbit and pig [137] and profiling has been conducted for plaque material removed in carotid endarterectomy [138].

The limited data available obstructs studies of atheroma at the macro scale and of the molecular biology involved. As a result, establishing biologically relevant kinetic parameters that can be used to simulate pathway dynamics is challenging and comprehensive parameterisations for the pathogenesis of atherosclerosis are not available in the public domain. As a consequence, some studies have resorted to estimating parameters for models, based on expert opinion or inferred from other cell processes.

It is likely that approximate values can be obtained for a number of the parameters required by using recombinant proteins and *in vitro* studies. However, recreating the environment of the *tunica intima* and quantifying its impact on the parameterisation in order to obtain physiological values will be challenging [139–141].

## Conclusion

Computational modelling of atherosclerosis presents an opportunity to contribute to the reduction of the global burden of CVD. By introducing accurate and quantitative models of atherosclerosis, we can create an *in silico* experimental system with the potential not only to displace *in vivo* and *in vitro* experimentation but also to enable us to study details that cannot be measured *in vivo* or *in vitro*. However this necessitates a physiologically accurate parameterisation and such data is not currently available in a comprehensive form.

Historically, little work has been completed developing computational modelling of atherosclerosis, although recent years have seen a clear growth of interest and the formation of a nascent field.



Here we have gathered together and reviewed the recent results with a view to identifying where the gaps in our understanding lie and where progress can be made.

Most of the work completed in this area to date has focussed on the inflammatory response and the shear stress of the artery wall and has involved modelling at a range of levels of abstraction.

The majority of work has focused on describing atheroma formation and few studies have addressed the mechanics of plaque rupture and its subsequent consequences. In most cases, models follow the canonical understanding of atherosclerosis: LDL penetration and oxidation, monocyte recruitment and differentiation and foam cell formation. However, many additional factors remain outside this canonical picture that are known to contribute to atherosclerosis and there currently exist opportunities to explore their role in the dynamics of this disease through computational modelling.

## **Acknowledgements**

We would like to acknowledge and thank Eliza Yankova (University of Ulster) for her assistance with Figure 1 (The pathophysiology of atherosclerosis).

## References

- 1 World Health Organisation - Mendis S Norrving B editors PP. Global Atlas on Cardiovascular Disease Prevention and Control. [http://whqlibdoc.who.int/publications/2011/9789241564373\\_eng.pdf?ua=1](http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf?ua=1) (3 August 2015, date last accessed)
- 2 Singh RB, Mengi SA, Xu YJ, *et al.* Pathogenesis of atherosclerosis: A multifactorial process. *Exp Clin Cardiol* 2002;**7**:40–53.
- 3 World Health Organisation. Cardiovascular Diseases Fact Sheet. <http://www.who.int/mediacentre/factsheets/fs317/en/> (3 August 2015, date last accessed)
- 4 Nichols M, Luengo-Fernandez R, Leal J *et al.*. European Cardiovascular Disease Statistics 2012. [http://www.escardio.org/static\\_file/Escardio/Press-media/press-releases/2013/EU-cardiovascular-disease-statistics-2012.pdf](http://www.escardio.org/static_file/Escardio/Press-media/press-releases/2013/EU-cardiovascular-disease-statistics-2012.pdf) (3 August 2015, date last accessed)
- 5 Postiglione A, Napoli C. Hyperlipidaemia and atherosclerotic cerebrovascular disease. *Curr Opin Lipidol* 1995;**6**:236–42.
- 6 Hansson G. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005;**353**:1685–95.
- 7 Hussein AA, Uno K, Wolski K, *et al.* Peripheral arterial disease and progression of coronary atherosclerosis. *J Am Coll Cardiol* 2011;**57**:1220–5.
- 8 World Heart Federation. Urbanization and Cardiovascular Disease Fact Sheet. <http://www.world-heart-federation.org/press/fact-sheets/urbanization-and-cardiovascular-disease/> (3 August 2015, date last accessed)
- 9 Mozaffarian D, Benjamin EJ, Go AS, *et al.* Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association. *Circulation* 2015;**131**:29–322.
- 10 World Health Organisation. Facts about aging. <http://www.who.int/ageing/about/facts/en/> (3 August 2015, date last accessed)
- 11 Grundy SM, Benjamin IJ, Burke GL, *et al.* Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* 1999;**100**:1134–46.
- 12 International Diabetes Federation. IDF Diabetes Atlas, 6th Edn. <http://www.idf.org/diabetesatlas> (3 August 2015, date last accessed)
- 13 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat Med* 2011;**17**:1410–22.
- 14 Libby P, Lichtman A, Hansson G. Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans. *Immunity*. 2013;**38**:1092–104.
- 15 Joris I, Majno G. Atherosclerosis and inflammation. *Adv Exp Med Biol* 1978;**104**:227–43.

- 16 Viggers RF, Wechezak AR, Sauvage LR. An apparatus to study the response of cultured endothelium to shear stress. *J Biomech Eng* 1986;**108**:332–7.
- 17 Boisvert WA. Modulation of atherogenesis by chemokines. *Trends Cardiovasc. Med.* 2004;**14**:161–5.
- 18 Kraemer R. Regulation of cell migration in atherosclerosis. *Curr Atheroscler Rep* 2000;**2**:445–52.
- 19 Yoshida H, Kisugi R. Mechanisms of LDL oxidation. *Clin. Chim. Acta.* 2010;**411**:1875–82.
- 20 Schrijvers DM, De Meyer GRY, Herman AG, *et al.* Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. *Cardiovasc Res* 2007;**73**:470–80.
- 21 Glagov S, Zarins C, Giddens DP, *et al.* Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. *Arch. Pathol. Lab. Med.* 1988;**112**:1018–31.
- 22 Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. *Lab Invest* 2005;**85**:9–23.
- 23 Blum A, Miller HI. The role of inflammation in atherosclerosis. *Isr J Med Sci* 1996;**32**:1059–65.
- 24 Auffray C, Hood L. Editorial: Systems biology and personalized medicine - the future is now. *Biotechnol J* 2012;**7**:938–9.
- 25 Aldridge BB, Burke JM, Lauffenburger DA, *et al.* Physicochemical modelling of cell signalling pathways. *Nat Cell Biol* 2006;**8**:1195–203.
- 26 Meng TC, Somani S, Dhar P. Modeling and simulation of biological systems with stochasticity. *In Silico Biol* 2004;**4**:293–309.
- 27 Watterson S, Marshall S, Ghazal P. Logic models of pathway biology. *Drug Discov. Today.* 2008;**13**:447–56.
- 28 Watterson S, Ghazal P. Use of logic theory in understanding regulatory pathway signaling in response to infection. *Future Microbiol* 2010;**5**:163–76.
- 29 Guerriero ML, Prandi D, Priami C, *et al.* Process Calculi Abstractions for Biology. In: *Algorithmic Bioprocesses.* 2009. 463–86.
- 30 Feret J, Danos V, Krivine J, *et al.* Internal coarse-graining of molecular systems. *Proc Natl Acad Sci U S A* 2009;**106**:6453–8.
- 31 Pedersen M, Plotkin G. A language for biochemical systems. In: *Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics).* 2008. 63–82.
- 32 Kwiatkowska MZ, Heath JK. Biological pathways as communicating computer systems. *J Cell Sci* 2009;**122**:2793–800.

- 33 Vert JP. Reconstruction of Biological Networks by Supervised Machine Learning Approaches. In: *Elements of Computational Systems Biology*. 2010. 165–88.
- 34 Grzegorzczak M, Husmeier D, Edwards KD, *et al.* Modelling non-stationary gene regulatory processes with a non-homogeneous Bayesian network and the allocation sampler. *Bioinformatics* 2008;**24**:2071–8.
- 35 Lewis NE, Schramm G, Bordbar A, *et al.* Large-scale in silico modeling of metabolic interactions between cell types in the human brain. *Nat Biotechnol* 2010;**28**:1279–85.
- 36 Ajmera I, Swat M, Laibe C, *et al.* The impact of mathematical modeling on the understanding of diabetes and related complications. *CPT Pharmacometrics Syst Pharmacol* 2013;**2**:e54.
- 37 Faratian D, Goltsov A, Lebedeva G, *et al.* Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. *Cancer Res* 2009;**69**:6713–20.
- 38 Nelson DE, Ihekweaba AE, Elliott M, *et al.* Oscillations in NF-kappaB signaling control the dynamics of gene expression. *Science* 2004;**306**:704–8.
- 39 Raza S, McDerment N, Lacaze PA, *et al.* Construction of a large scale integrated map of macrophage pathogen recognition and effector systems. *BMC Syst Biol* 2010;**4**:63.
- 40 Thiele I, Swainston N, Fleming RM, *et al.* A community-driven global reconstruction of human metabolism. *Nat Biotechnol* 2013;**31**:419–25.
- 41 Mitchell S, Mendes P. A computational model of liver iron metabolism. *PLoS Comput Biol* 2013;**9**:e1003299.
- 42 Karr JR, Sanghvi JC, Macklin DN, *et al.* A whole-cell computational model predicts phenotype from genotype. *Cell* 2012;**150**:389–401.
- 43 Hucka M, Finney A, Sauro HM, *et al.* The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. *Bioinformatics* 2003;**19**:524–31.
- 44 Finney A, Hucka M. Systems biology markup language: Level 2 and beyond. *Biochem Soc Trans* 2003;**31**:1472–3.
- 45 Cuellar AA, Lloyd CM, Nielsen PF, *et al.* An overview of CellML 1.1, a biological model description language. *Simulation-Transactions Soc Model Simul Int* 2003;**79**:740–7.
- 46 Le Novère N, Hucka M, Mi H, *et al.* The Systems Biology Graphical Notation. *Nat Biotechnol* 2009;**27**:735–41.
- 47 Van Iersel MP, Villéger AC, Czauderna T, *et al.* Software support for SBGN maps: SBGN-ML and LibSBGN. *Bioinformatics* 2012;**28**:2016–21.
- 48 Le Novère N, Finney A, Hucka M, *et al.* Minimum information requested in the annotation of biochemical models (MIRIAM). *Nat Biotechnol* 2005;**23**:1509–15.

- 49 Waltemath D, Adams R, Beard DA, *et al.* Minimum information about a simulation experiment (MIASE). *PLoS Comput Biol* 2011;**7**.
- 50 Le Novere N, Bornstein B, Broicher A, *et al.* BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems. *Nucleic Acids Res* 2006;**34**:D689–91.
- 51 Bhattacharya BS, Sweby PK, Minihane AM, *et al.* A mathematical model of the sterol regulatory element binding protein 2 cholesterol biosynthesis pathway. *J Theor Biol* 2014;**349**:150–62.
- 52 Mazein A, Watterson S, Hsieh WY, *et al.* A comprehensive machine-readable view of the mammalian cholesterol biosynthesis pathway. *Biochem Pharmacol* 2013;**86**:56–66.
- 53 Watterson S, Guerriero ML, Blanc M, *et al.* A model of flux regulation in the cholesterol biosynthesis pathway: Immune mediated graduated flux reduction versus statin-like led stepped flux reduction. *Biochimie* 2013;**95**:613–21.
- 54 Lu H, Talbot S, Robertson KA, *et al.* Rapid proteasomal elimination of 3-hydroxy-3-methylglutaryl-CoA reductase by interferon-gamma in primary macrophages requires endogenous 25-hydroxycholesterol synthesis. *Steroids* Published Online First: 2015.
- 55 Mc Auley MT, Wilkinson DJ, Jones JJ, *et al.* A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. *BMC Syst Biol* 2012;**6**:130.
- 56 Mc Auley MT, Mooney KM. Computationally Modeling Lipid Metabolism and Aging: A Mini-review. *Comput Struct Biotechnol J* 2015;**13**:38–46.
- 57 Douglas G, Channon KM. The pathogenesis of atherosclerosis. *Medicine (Baltimore)* 2014;**42**:480–4.
- 58 Lusis AJ. Atherosclerosis. *Nature* 2000;**407**:233–41.
- 59 Alexander RW. Hypertension and the Pathogenesis of Atherosclerosis : Oxidative Stress and the Mediation of Arterial Inflammatory Response: A New Perspective. *Hypertension*. 1995;**25**:155–61.
- 60 Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. *Vasc Med* 1998;**3**:21–8.
- 61 Harrison D, Griendling KK, Landmesser U, *et al.* Role of oxidative stress in atherosclerosis. *Am J Cardiol* 2003;**91**:7A – 11A.
- 62 Goriely A, Vandiver R. On the mechanical stability of growing arteries. *IMA J Appl Math (Institute Math Its Appl)* 2010;**75**:549–70.
- 63 Nabel EG, Ganz P, Gordon JB, *et al.* Dilatation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. *Circulation* 1988;**77**:43–52.
- 64 Li ZY, Howarth SPS, Tang T, *et al.* How critical is fibrous cap thickness to carotid plaque stability? A flow-plaque interaction model. *Stroke* 2006;**37**:1195–9.

- 65 Resnick N, Yahav H, Shay-Salit A. Fluid shear stress and the vascular endothelium: for better and for worse. *Prog Biophys Mol Biol* 2003;**81**:177–99.
- 66 Stroud JS, Berger SA, Saloner D. Numerical analysis of flow through a severely stenotic carotid artery bifurcation. *J Biomech Eng* 2002;**124**:9–20.
- 67 Tomaso G Di, Diaz-Zuccarini V, Pichardo-Almarza C. A Multiscale Model of Atherosclerotic Plaque Formation at Its Early Stage. *IEEE Trans Biomed Eng* 2011;**58**:3460–3.
- 68 Cilla M, Peña E, Martínez MA. Mathematical modelling of atheroma plaque formation and development in coronary arteries. *J R Soc Interface* 2014;**11**:20130866.
- 69 Ethier CR. Computational modeling of mass transfer and links to atherosclerosis. *Ann Biomed Eng* 2002;**30**:461–71.
- 70 Filipovic N, Kojic M. Computer simulations of blood flow with mass transport through the carotid artery bifurcation. *Theor Appl Mech* 2004;**31**:1–33.
- 71 Filipovic N, Meunier N, Fotiadis D, *et al.* Three-dimensional Numerical Simulation of Plaque Formation in the Arteries. *Computational Surgery and Dual Training*. 2014;257-264
- 72 Johnston BM, Johnston PR, Corney S, *et al.* Non-Newtonian blood flow in human right coronary arteries: Transient simulations. *J Biomech* 2006;**39**:1116–28.
- 73 Liu B, Tang D. Computer Simulations of Atherosclerotic Plaque Growth in Coronary Arteries. *Mol Cell Biomech* 2010;**7**:193–202.
- 74 Olgac U, Kurtcuoglu V, Poulikakos D. Computational modeling of coupled blood-wall mass transport of LDL: effects of local wall shear stress. *Am J Physiol Heart Circ Physiol* 2008;**294**:H909–19.
- 75 Rappitsch G, Perktold K, Pernkopf E. Numerical Modelling of Shear-Dependent Mass Transfer in Large Arteries. *International Journal for Numerical Methods in Fluids* 1997;**857**:847–57.
- 76 Sun N, Wood NB, Hughes AD, *et al.* Fluid-wall modelling of mass transfer in an axisymmetric Stenosis: Effects of shear-dependent transport properties. *Ann Biomed Eng* 2006;**34**:1119–28.
- 77 Ai L, Vafai K. A coupling model for macromolecule transport in a stenosed arterial wall. *Int J Heat Mass Transf* 2006;**49**:1568–91.
- 78 Wada S, Koujiya M, Karino T. Theoretical study of the effect of local flow disturbances on the concentration of low-density lipoproteins at the luminal surface of end-to-end anastomosed vessels. *Med Biol Eng Comput* 2002;**40**:576–87.
- 79 Wang HH. Analytical models of atherosclerosis. *Atherosclerosis* 2001;**159**:1–7.
- 80 Calvez V, Ebde A. Mathematical modelling of the atherosclerotic plaque formation. *ESAIM Proc* 2010;:1–16.
- 81 Vincent Calvez Nicolas Meunier, Annie Raoult and Gabriela Rusnakova JGH. Mathematical and numerical modelling of early atherosclerotic lesions. *ESAIM Proc* 2010;**30**:1–14.

- 82 Quarteroni A, Veneziani A, Zunino P. Mathematical and Numerical Modeling of Solute Dynamics in Blood Flow and Arterial Walls. *SIAM J. Numer. Anal.* 2002;**39**:1488–511.
- 83 Bosnić Z, Vračar P, Radovi MD, *et al.* Mining data from hemodynamic simulations for generating prediction and explanation models. *IEEE Trans Inf Technol Biomed* 2012;**16**:248–54.
- 84 Bulelzi MA, Dubbeldam JL. Long time evolution of atherosclerotic plaques. *J Theor Biol* 2012;**297**:1–10.
- 85 Gabriel SA, Ding Y, Feng Y, *et al.* Deposition-driven Growth in Atherosclerosis Modelling. *19th Australasian Fluid Mechanics Conference*. 2014;:2–5.
- 86 Silva T, Sequeira A, Santos RF, *et al.* Mathematical Modeling of Atherosclerotic Plaque Formation Coupled with a Non-Newtonian Model of Blood Flow. *Conf Pap Med* 2013;**2013**:1–14.
- 87 Gessaghi VC, Raschi MA, Tanoni DY, *et al.* Growth model for cholesterol accumulation in the wall of a simplified 3D geometry of the carotid bifurcation. *Comput Methods Appl Mech Eng* 2011;**200**:2117–25.
- 88 Green J, Waters S, Cummings L, *et al.* Atherosclerotic plaque rupture. *UK MMSG Nottingham 2002*. Published Online First: 2002. <http://www.maths-in-medicine.org/uk/2002/plaque-rupture/report.pdf> (3 August 2015, date last accessed)
- 89 Deepa TK, Binu LS, Sukesh AK. Modelling Blood Flow and Analysis of Atherosclerotic Plaque Rupture under G-Force. *2009 3rd Int Conf Bioinforma Biomed Eng* 2009;:1–4.
- 90 Girke S, Kloforn R, Ohlberger M. Efficient Parallel Simulation of Atherosclerotic Plaque Formation Using Higher Order Discontinuous Galerkin Schemes. *Finite Vol. Complex Appl. VII-Elliptic, Parabol. Hyperbolic Probl.* 2014;:Volume 78, pp 617–25.
- 91 McKay C, McDee S, Mottram N, *et al.* Towards a Model of Atherosclerosis. *Univ Strat* 2005;:1–29.
- 92 Calvez V, Ebde A, Meunier N, *et al.* Mathematical modelling of the atherosclerotic plaque formation. *ESAIM Proc* 2010;**30**:1–14.
- 93 Ibragimov AI, McNeal CJ, Ritter LR, *et al.* A mathematical model of atherogenesis as an inflammatory response. *Math Med Biol* 2005;**22**:305–33.
- 94 Cobbold CA, Sherratt JA, Maxwell SR. Lipoprotein oxidation and its significance for atherosclerosis: a mathematical approach. *Bull Math Biol* 2002;**64**:65–95.
- 95 Prosi M, Zunino P, Perktold K, *et al.* Mathematical and numerical models for transfer of low-density lipoproteins through the arterial walls: a new methodology for the model set up with applications to the study of disturbed luminal flow. *J Biomech* 2005;**38**:903–17.
- 96 Friedman A, Hao W. A Mathematical Model of Atherosclerosis with Reverse Cholesterol Transport and Associated Risk Factors. *Bull Math Biol* Published Online First: 2014.

- 97 Hao W, Friedman A. The LDL-HDL profile determines the risk of atherosclerosis: a mathematical model. *PLoS One* 2014;**9**:e90497.
- 98 Filipovic N, Teng Z, Radovic M, *et al.* Computer simulation of three-dimensional plaque formation and progression in the carotid artery. *Med Biol Eng Comput* 2013;**51**:607–16.
- 99 Filipovic N, Fotiadis D, Pelosi W, *et al.* Experimental and computer model of plaque formation in the artery. *10th Int Work Biomed Eng BioEng 2011* 2011;:1–4.
- 100 Ougrinovskaia A, Thompson RS, Myerscough MR. An ODE model of early stages of atherosclerosis: mechanisms of the inflammatory response. *Bull Math Biol* 2010;**72**:1534–61.
- 101 Cohen A, Myerscough MR, Thompson RS. Athero-protective effects of High Density Lipoproteins (HDL): An ODE model of the early stages of atherosclerosis. *Bull Math Biol* 2014;**76**:1117–42.
- 102 Zohdi TI, Holzapfel GA, Berger SA. A phenomenological model for atherosclerotic plaque growth and rupture. *J Theor Biol* 2004;**227**:437–43.
- 103 Little MP, Gola A, Tzoulaki I. A model of cardiovascular disease giving a plausible mechanism for the effect of fractionated low-dose ionizing radiation exposure. *PLoS Comput Biol* 2009;**5**.
- 104 El Khatib N, Génieys S, Volpert V. Atherosclerosis Initiation Modeled as an Inflammatory Process. *Math Model Nat Phenom* 2007;**2**:126–41.
- 105 Zhang S, Ritter LR, Ibragimov AI. Foam cell formation in atherosclerosis: HDL and macrophage reverse cholesterol transport. *Discret Contin Dyn Syst - Ser S* 2013;:825–35.
- 106 Lichtman AH, Chin J, Schmidt JA, *et al.* Role of interleukin 1 in the activation of T lymphocytes. *Proc Natl Acad Sci U S A* 1988;**85**:9699–703.
- 107 McLaren JE, Ramji DP. Interferon gamma: A master regulator of atherosclerosis. *Cytokine Growth Factor Rev.* 2009;**20**:125–35.
- 108 Fok P-W. Mathematical model of intimal thickening in atherosclerosis: vessel stenosis as a free boundary problem. *J Theor Biol* 2012;**314**:23–33.
- 109 Xue C, Friedman A, Sen CK. A mathematical model of ischemic cutaneous wounds. *Proc Natl Acad Sci U S A* 2009;**106**:16782–7.
- 110 Guy RD, Fogelson AL, Keener JP. Fibrin gel formation in a shear flow. *Math Med Biol* 2007;**24**:111–30.
- 111 Chelliah V, Juty N, Ajmera I, *et al.* BioModels: ten-year anniversary. *Nucleic Acids Res* 2015;**43**:D542–8.
- 112 Li C, Donizelli M, Rodriguez N, *et al.* BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. *BMC Syst Biol* 2010;**4**:92.
- 113 Yu T, Lloyd CM, Nickerson DP, *et al.* The Physiome Model Repository 2. *Bioinformatics* 2011;**27**:743–4.



- 114 Shaw GM, Chase JG, Starfinger C, *et al.* Modelling the cardiovascular system. *Crit. Care Resusc.* 2007;**9**:264–9.
- 115 Bucher J, Riedmaier S, Schnabel A, *et al.* A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes. *BMC Syst Biol* 2011;**5**:66.
- 116 Gotto AM. Triglyceride as a risk factor for coronary artery disease. *Am J Cardiol* 1998;**82**:25.
- 117 Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. *Curr Cardiol Rep* 2011;**13**:544–52.
- 118 Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis. *Curr. Atheroscler. Rep.* 2007;**9**:110–5.
- 119 Umaerus M, Rosengren B, Fagerberg B, *et al.* HDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effect. *Atherosclerosis* 2012;**225**:115–20.
- 120 Umemoto T, Han CY, Mitra P, *et al.* Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. *Circ Res* 2013;**112**:1345–54.
- 121 Otvos JD, Mora S, Shalaurova I, *et al.* Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. *J Clin Lipidol* 2011;**5**:105–13.
- 122 Hartwig H, Silvestre Roig C, Daemen M, *et al.* Neutrophils in atherosclerosis. A brief overview. *Hamostaseologie* 2014;**35**.
- 123 Perry HM, Bender TP, McNamara CA. B cell subsets in atherosclerosis. *Front Immunol* 2012;**3**:373.
- 124 Xu Q, Metzler B, Jahangiri M, *et al.* Molecular chaperones and heat shock proteins in atherosclerosis. *Am J Physiol Hear Circ Physiol* 2012;**302**:506–14.
- 125 Kilic A, Mandal K. Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications. *Autoimmune Dis* 2012;**2012**:502813.
- 126 Xiao H, Lu M, Yang T, *et al.* SREBP2 Activation of NLRP3 Inflammasome in Endothelium Mediates Hemodynamic-Induced Atherosclerosis Susceptibility. *Circulation* 2013;**128**:632–42.
- 127 Nazari-Jahantigh M, Egea V, Schober A, *et al.* MicroRNA-specific regulatory mechanisms in atherosclerosis. *J Mol Cell Cardiol* Published Online First: 2014.
- 128 Tatonetti NP, Liu T, Altman RB. Predicting drug side-effects by chemical systems biology. *Genome Biol* 2009;**10**:238.
- 129 Wang K, Sun J, Zhou S, *et al.* Prediction of Drug-Target Interactions for Drug Repositioning Only Based on Genomic Expression Similarity. *PLoS Comput Biol* 2013;**9**.

- 130 Yang L, Wang K, Chen J, *et al.* Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome - clozapine-induced agranulocytosis as a case study. *PLoS Comput Biol* 2011;**7**.
- 131 Sun X, Vilar S, Tatonetti NP. High-throughput methods for combinatorial drug discovery. *Sci Transl Med* 2013;**5**:205rv1.
- 132 Eussen SR, Rempelberg CJ, Klungel OH, *et al.* Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans. *Lipids Health Dis* 2011;**10**:187.
- 133 Chua HN, Roth FP. Discovering the targets of drugs via computational systems biology. *J Biol Chem* 2011;**286**:23653–8.
- 134 Holzapfel GA, Gasser TC, Ogden RW. A new constitutive framework for arterial wall mechanics and a comparative study of material models. *J Elast* 2000;**61**:1–48.
- 135 Eftaxiopoulos DA, Atkinson C. A nonlinear, anisotropic and axisymmetric model for balloon angioplasty. *Proc R Soc A Math Phys Eng Sci* 2005;**461**:1097–128.
- 136 Schunkert H, König IR, Kathiresan S, *et al.* Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet* 2011;**43**:333–8.
- 137 Getz GS, Reardon CA. Animal models of Atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 2012;**32**:1104–15.
- 138 Verhoeven BA, De Vries JP, Pasterkamp G, *et al.* Carotid atherosclerotic plaque characteristics are associated with microembolization during carotid endarterectomy and procedural outcome. *Stroke* 2005;**36**:1735–40.
- 139 Yang M, Chesterman CN, Chong BH. Recombinant PDGF enhances megakaryocytopoiesis in vitro. *Br J Haematol* 1995;**91**:285–9.
- 140 Rollins BJ, Walz A, Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. *Blood* 1991;**78**:1112–6.
- 141 Santoli D, Yang YC, Clark SC, *et al.* Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. *J Immunol* 1987;**139**:3348–54.
- 142 Schulze-Bauer CAJ, Mörth C, Holzapfel GA. Passive biaxial mechanical response of aged human iliac arteries. *J Biomech Eng* 2003;**125**:395–406.
- 143 Ahmed SA, Giddens DP. Velocity measurements in steady flow through axisymmetric stenoses at moderate Reynolds numbers. *J Biomech* 1983;**16**:505–16.
- 144 Meyer G, Merval R, Tedgui A. Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. *Circ Res* 1996;**79**:532–40.

- 145 Bousset L, Arora S, Rapp J, *et al.* Atherosclerotic plaque progression in carotid arteries: monitoring with high-spatial-resolution MR imaging--multicenter trial. *Radiology* 2009;**252**:789–96.
- 146 Kirpalani A, Park H, Butany J, *et al.* Velocity and wall shear stress patterns in the human right coronary artery. *J Biomech Eng* 1999;**121**:370–5.
- 147 Myers JG, Moore JA, Ojha M, *et al.* Factors influencing blood flow patterns in the human right coronary artery. *Ann Biomed Eng* 2001;**29**:109–20.
- 148 Huang Y, Rumschitzki D, Chien S, *et al.* A fiber matrix model for the filtration through fenestral pores in a compressible arterial intima. *Am J Physiol* 1997;**272**:H2023–39.
- 149 Yuan F, Chien S, Weinbaum S. A new view of convective-diffusive transport processes in the arterial intima. *J Biomech Eng* 1991;**113**:314–29.
- 150 Friedman MH, Ehrlich LW. Effect of spatial variations in shear on diffusion at the wall of an arterial branch. *Circ Res* 1975;**37**:446–54.
- 151 Ishibashi H, Sunamura M, Karino T. Flow patterns and preferred sites of intimal thickening in end-to-end anastomosed vessels. *Surgery* 1995;**117**:409–20.
- 152 Budu-Grajdeanu P, Schugart RC, Friedman A, *et al.* A mathematical model of venous neointimal hyperplasia formation. *Theor Biol Med Model* 2008;**5**:2.
- 153 Hecht F. New development in freefem+. *J Numer Math* 2012;**20**:251–65.
- 154 Cheng C, Van Haperen R, De Waard M, *et al.* Shear stress affects the intracellular distribution of eNOS: Direct demonstration by a novel in vivo technique. *Blood* 2005;**106**:3691–8.
- 155 Cheng C, Tempel D, Van Haperen R, *et al.* Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. *Circulation* 2006;**113**:2744–53.
- 156 Dhooge A, Govaerts W, Kuznetsov YA. MATCONT: A MATLAB package for numerical bifurcation analysis of ODEs. *ACM Trans Math Softw* 2003;**29**:141–64.
- 157 Chen J, Lu XY. Numerical investigation of the non-Newtonian blood flow in a bifurcation model with a non-planar branch. *J Biomech* 2004;**37**:1899–911.
- 158 Yang N, Vafai K. Modeling of low-density lipoprotein (LDL) transport in the artery-effects of hypertension. *Int J Heat Mass Transf* 2006;**49**:850–67.
- 159 Weller HG, Tabor G. A tensorial approach to computational continuum mechanics using object-oriented techniques. *Comput Phys* 1998;**12**:620–31.
- 160 Dedner A, Klöfkor R, Nolte M, *et al.* A generic interface for parallel and adaptive discretization schemes: Abstraction principles and the Dune-Fem module. *Comput (Vienna/New York)* 2010;**90**:165–96.

- 161 Neužil J, Thomas SR, Stocker R. Requirement for, promotion, or inhibition by  $\alpha$ -tocopherol of radical- induced initiation of plasma lipoprotein lipid peroxidation. *Free Radic Biol Med* 1996;**22**:57–71.
- 162 Lovren F, Pan Y, Quan A, *et al.* MicroRNA-145 targeted therapy reduces atherosclerosis. *Circulation* 2012;**126**.
- 163 Feig JE, Rong JX, Shamir R, *et al.* HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. *Proc Natl Acad Sci U S A* 2011;**108**:7166–71.
- 164 Schiopu A, Freundés B, Jansson B, *et al.* Recombinant Antibodies to an Oxidized Low-Density Lipoprotein Epitope Induce Rapid Regression of Atherosclerosis in Apobec-1-/-/Low-Density Lipoprotein Receptor-/- Mice. *J Am Coll Cardiol* 2007;**50**:2313–8.
- 165 Cushing SD, Berliner JA, Valente AJ, *et al.* Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. *Proc Natl Acad Sci U S A* 1990;**87**:5134–8.
- 166 Shi Q, Vandeberg JF, Jett C, *et al.* Arterial endothelial dysfunction in baboons fed a high-cholesterol, high-fat diet. *Am J Clin Nutr* 2005;**82**:751–9.
- 167 Stadius ML, Rowan R, Fleischhauer JF, *et al.* Time course and cellular characteristics of the iliac artery response to acute balloon injury. An angiographic, morphometric, and immunocytochemical analysis in the cholesterol-fed New Zealand white rabbit. *Arterioscler Thromb* 1992;**12**:1267–73.
- 168 Roy S, Biswas S, Khanna S, *et al.* Characterization of a preclinical model of chronic ischemic wound. *Physiol Genomics* 2009;**37**:211–24.

**Table 1****A summary of the mathematical models of atherosclerosis referenced within this review.**

These models are reproducible as their governing equations are explained in the cited references.

<b>First Author</b>	<b>Title</b>	<b>Year</b>	<b>Form</b>	<b>Parameters</b>	<b>Validation</b>	<b>Tools</b>
Goriely [62]	On the mechanical stability of growing arteries	2010	A coronary artery modelled as an incompressible 2-layer cylindrical structure was used to study the arterial response to stress	Related to experimental data	Compared to experimental data obtained by Schulze-Bauer et al. [142]	None mentioned
Li [64]	How critical is fibrous cap thickness to carotid plaque stability? A flow-plaque interaction model	2006	A model of a stenotic carotid artery was used to relate fibrous cap thickness to WSS	Use a combination of estimated and experimentally validated parameters	The authors claim that the model fits well within the current literature, however no references are given to substantiate this claim	FEMLAB was used for model construction, SPSS was used to analyse this model
Stroud [66]	Numerical analysis of flow through a severely stenotic carotid artery bifurcation	2002	A model of a carotid artery bifurcation is used to study pulsatile and steady blood flow	Related to experimental data	Compared to experimental data obtained by Ahmed and Giddens [143]	None mentioned
Quarteroni [82]	Mathematical and numerical	2002	Proposed two models of an	Parameter source unclear	None	None mentioned

First Author	Title	Year	Form	Parameters	Validation	Tools
	modeling of solute dynamics in blood flow and arterial walls		arterial bifurcation to study mass transfer			
Di Tomaso [67]	A Multiscale Model of Atherosclerotic Plaque Formation at Its Early Stage	2011	Built a multi-scale model of atherosclerosis to include mass transfer, LDL oxidation and foam cell formation	Use a combination of estimated and experimentally validated parameters	The model was compared with experimental data taken from Meyer <i>et al.</i> [144] and against the model produced by Olgac <i>et al.</i> [74]	None mentioned
Cilla [68]	Mathematical modelling of atheroma plaque formation and development in coronary arteries	2013	Uses a standard left descending coronary artery model to study plaque growth	Taken from experimental data and other mathematical models	Parts of the model correspond with experimental data such as Meyer <i>et al.</i> [144], however appropriate experimental data to cover the entire model is not currently available.	COMSOL Multiphysics
Filipovic [70]	Computer simulations of blood flow with mass transport through the carotid artery bifurcation	2004	Proposed a simulation of mass transport to allow physicians to study individual patients	Parameter source unclear	The authors claim that the model fits well within the current literature, however no references are given to substantiate this claim	None mentioned

First Author	Title	Year	Form	Parameters	Validation	Tools
Filipovic [71]	ARTreat Project: Three-Dimensional Numerical Simulation of Plaque Formation and Development in the Arteries	2012	Presented a 3D model of plaque formation and development	Parameters were experimentally established through a rabbit animal model	Plaque progression within the model has been validated against experimental data taken from Bousset <i>et al.</i> [145]	None mentioned
Johnston [72]	Non-Newtonian blood flow in human right coronary arteries: Transient simulations	2005	Used right coronary artery models to study pulsatile blood flow	Experimentally observed	Findings were validated against experimental data taken from Kirpalani <i>et al.</i> [146] & Myers <i>et al.</i> [147]	CFD-ACE
Liu [73]	Computer Simulations of Atherosclerotic Plaque Growth in Coronary Arteries	2010	Uses model of a stenosis-free curved human coronary artery to study plaque growth	Experimentally observed	None	COMSOL Multiphysics
Olgac [74]	Computational modeling of coupled blood-wall mass transport of LDL: effects of local wall shear stress	2008	Developed a model of a stenosed coronary artery to study the effects of WSS on mass transport	Experimentally observed	Related to experimental data Meyer <i>et al.</i> [144], Huang <i>et al.</i> [148], Yuan <i>et al.</i> [149]	COMSOL Multiphysics
Rappitsch [75]	Numerical Modelling of Shear-Dependent Mass Transfer in Large Arteries	1997	Used a curved-tube-artery model to study blood flow and lipoprotein transport processes	Use a combination of estimated and experimentally validated parameters	Validated against Friedman <i>et al.</i> [150]	None mentioned

First Author	Title	Year	Form	Parameters	Validation	Tools
Sun [76]	Fluid-wall modelling of mass transfer in an axisymmetric Stenosis: Effects of shear-dependent transport properties	2006	Studies the influence of WSS on mass transport	Use a combination of estimated and experimentally validated parameters	Compared to experimental data taken from rabbit aortic walls Meyer <i>et al.</i> [144]	None mentioned
Ai [77]	A coupling model for macromolecule transport in a stenosed arterial wall	2006	A model of a stenosed artery is used to study lipid transfer	Experimentally validated	Compared to other mathematical models, with arguments as to why their parameter set is more accurate	FIDAP
Wada [78]	Theoretical study of the effect of local flow disturbances on the concentration of low-density lipoproteins at the luminal surface of end-to-end anastomosed vessels.	2002	Femoral artery model is used to study the relationship between intimal thickness and the endothelial surface level of LDL	Parameters were taken from experimental data or estimated	Compared to experimental data taken from Ishibashi <i>et al.</i> [151]	Star LT
Calvez [80]	Mathematical modelling of the atherosclerotic	2009	Developed a 2D geometry modelling the	Parameters are taken from other mathematical	None	FreeFem++ [153]



First Author	Title	Year	Form	Parameters	Validation	Tools
	plaque formation.		carotid artery to demonstrate plaque formation, based on the model of El Khatib <i>et al.</i> [104]	models, relating to atherosclerosis [104] and hyperplasia [152]		
Calvez [81]	Mathematical and numerical modelling of early atherosclerotic lesions	2010	Expanded on their previous model [80] to include a model of lesion growth	Parameters were taken from experimental data or estimated	Experiments published by Cheng <i>et al.</i> [154, 155] were reproduced and were used to validate the model	FreeFem++ [153]
Bosnić [83]	Mining data from hemodynamic simulations for generating prediction and explanation models.	2012	Built a prototype of a system that could predict locations of increased WSS from artery models	Parameter source unclear	Presents a series of methods to estimate accuracy of the model, and relates these to experimental data	None mentioned
Bulelzai [84]	Long time evolution of atherosclerotic plaques	2011	Present a series of ODEs for the concentrations of particular elements of atheromae.	Taken from experimental data and other mathematical models [91]	Compared to mathematical model of Zohdi <i>et al.</i> [102]	MATCONT [156]
Gabriel [85]	Deposition-driven Growth in Atherosclerosis Modelling.	2014	A simplified bifurcating artery is used to model LDL flux into the intima	Taken from experimental data	None	ANSYS Fluent
Silva [86]	Mathematical Modeling of Atherosclerotic	2013	Built a 2D carotid artery bifurcation to study plaque	Taken from other mathematical models [157]	None	COMSOL Multiphysics

First Author	Title	Year	Form	Parameters	Validation	Tools
	Plaque Formation Coupled with a Non-Newtonian Model of blood Flow		formation with a non-Newtonian model of blood flow			
Gessaghi [87]	Growth model for cholesterol accumulation in the wall of a simplified 3D geometry of the carotid bifurcation	2011	A 3D model of a carotid artery bifurcation is used to study the influx, efflux, oxidation and phagocytosis of LDL	Taken from experimental data	Compared with data obtained from Yang <i>et al.</i> [158]. However, authors comment that not enough experimental data exists to fully validate the model.	OpenFOAM [159], Netgen
Green [88]	Atherosclerotic plaque rupture	2002	A model of a straight, stenotic 2D artery is used to study atherosclerotic plaque rupture.	Parameter source unclear	None	AUTO
Deepa [89]	Modelling Blood Flow and Analysis of Atherosclerotic Plaque Rupture under G-Force	2009	A 1D arterial model was used to study the rupture of plaques under g-force	Sources have not been cited for parameter values	None	MATLAB
Girke [90]	Efficient Parallel Simulation of Atherosclerotic Plaque Formation Using Higher Order Discontinuous Galerkin Schemes	2014	Girke <i>et al.</i> built a mathematical model based on the works of Ibragimov <i>et al.</i> [93] and Calvez <i>et al.</i> [81] to	Taken from experimental data	None	DUNE-FEM [160]

First Author	Title	Year	Form	Parameters	Validation	Tools
			demonstrate the use of the compact discontinuous galerkin method (CDG2) in discretizing relevant equations			
McKay [91]	Towards a Model of Atherosclerosis	2005	Proposed a mathematical model to cover mass transfer, oxidation, immune cell activation and plaque growth	Taken from other mathematical models, or estimated by domain experts	None	None mentioned
Ibragimov [93]	A mathematical model of atherogenesis as an inflammatory response	2005	Created a series of ODEs to study the concentrations of cell groups over time	Primarily estimated due to lack of relevant data	None	FEMLAB
Cobbold [94]	Lipoprotein Oxidation and its Significance for Atherosclerosis: a Mathematical Approach	2002	Built a series of ODEs to study lipoprotein oxidation	Taken from experimental data	Compared to an experiment performed by Neužil <i>et al.</i> [161]	None mentioned
Prosi [95]	Mathematical and numerical models for transfer of low density lipoproteins through the arterial walls: a new	2004	Built multiple models of lipoprotein transfer in order to maximise the accuracy of their prediction	Taken from experimental data	Experimentally validated against Meyer <i>et al.</i> [144]	None mentioned

First Author	Title	Year	Form	Parameters	Validation	Tools
	methodology for the model set up with applications to the study of disturbed luminal flow					
Friedman [96]	A Mathematical Model of Atherosclerosis with Reverse Cholesterol Transport and Associated Risk Factors	2014	Expands on the previous model by the same group [97] to include reverse cholesterol transport	Taken from experimental data and from other mathematical models [97]	Validated qualitatively against experimental data (e.g. [162–164])	None mentioned
Hao [97]	The LDL-HDL profile determines the risk of atherosclerosis: a mathematical model	2014	Developed a series of PDEs to model the concentration of a series of cells and macromolecules contained within an atheroma, and related this information to plaque growth	Taken from experimental data or estimated	None	MATLAB
Filipovic [99]	Experimental and computer model of plaque formation in the artery	2011	Built a model of plaque formation based on a pig left anterior descending coronary artery	Taken from experimental data, or estimated where data was unavailable.	Reproduced an experiment by Cheng <i>et al.</i> [155] and compared the results to their model of plaque formation	None explained

First Author	Title	Year	Form	Parameters	Validation	Tools
Ougrinovskaia [100]	An ODE model of early stages of atherosclerosis: mechanisms of the inflammatory response	2010	Developed a series of ODEs to model mass transfer and foam cell formation	Estimated	Behaviour relates to qualitative data, but model has not been compared to quantitative data	MATLAB, XPPAUTO
Cohen [101]	Athero-protective effects of High Density Lipoproteins (HDL): An ODE model of the early stages of atherosclerosis	2014	Expanded on their previous model [100] to include HDL and reverse cholesterol transport	Taken from experimental data	Noted that the behaviour of their model corresponds with an experiment performed by Feig <i>et al.</i> [163]	None mentioned
Zohdi [102]	A phenomenological model for atherosclerotic plaque growth and rupture	2004	Built a series of equations to study plaque growth and lesion rupture	Taken from experimental data, or estimated where data was unavailable.	None	None mentioned
Little [103]	A model of cardiovascular disease giving a plausible mechanism for the effect of fractionated low-dose ionizing radiation exposure	2009	Built a series of equations to study the effect of small radiation doses to atherosclerosis and CVD	Taken from experimental data	Sections of this model are validated by matching with experimental data published by Cushing <i>et al.</i> [165] and Shi <i>et al.</i> [166]	None mentioned
El Khatib [104]	Atherosclerosis Initiation Modeled as an Inflammatory Process	2007	Built a series of reaction-diffusion equations by grouping together	Estimated	None	COMSOL Multiphysics

First Author	Title	Year	Form	Parameters	Validation	Tools
			all cytokines and immune cells involved			
Zhang [105]	Foam cell formation in atherosclerosis: HDL and macrophage reverse cholesterol transport	2013	Expanded on the model of Ibragimov <i>et al.</i> [93] by focusing on the role of HDL and reverse cholesterol transport	Taken from experimental data and from other mathematical models [94]	None	None mentioned
Fok [108]	Mathematical model of intimal thickening in atherosclerosis: vessel stenosis as a free boundary problem	2012	Focuses on SMC migration and the role of PDGF	Taken from experimental data	Compared to experimental data taken from New Zealand white rabbits Stadius <i>et al.</i> [167]	None mentioned
Xue [109]	A mathematical model of ischemic cutaneous wounds	2009	Xue <i>et al.</i> developed a series of PDEs to model ischemic dermal wounds	A combination of experimentally validated and estimated parameters are used	Compared to experimental data established by Roy <i>et al.</i> [168]	Livermore Solver
Guy [110]	Fibrin gel formation in a shear flow	2007	Presents a model of fibrin formation in a damaged blood vessel	A combination of experimentally validated and estimated parameters are used	None	None mentioned




Figure 1: The

**pathophysiology of atherosclerosis.** Low density lipoproteins (LDL) transfer into the artery wall at a site of endothelial damage. Arterial wall shear stress (WSS) and its relationship to lipoprotein transfer into the artery wall has been studied by Liu *et al.* Lipoproteins pass into the artery wall at a rate dependent on WSS, lipoprotein diffusivity and lipoprotein concentration, as modeled by Sun *et al.* After entering the intima, lipoproteins become oxidized upon contact with free oxygen radicals, a process that has been modeled by Cobbold *et al.* Monocytes are recruited to the site of inflammation via MCP-1 (modeled by Cilla *et al.*) and pass into the intima before differentiating into macrophages (Bulelzai *et al.*), catalyzed by T-Cell produced IFN- $\gamma$  (Hao *et al.*). Macrophages phagocytose oxidized LDL within the artery wall, forming cholesterol-laden foam cells (Zhang *et al.*). Foam cells secrete MCP-1, which recruits more monocytes to the lesion, and PDGF, which recruits smooth muscle cells (SMCs) into the intima (Fok *et al.*).